Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its use of diverse ...

Mallinckrodt Pharmaceuticals and Endo Inc. are exploring a potential merger that could be valued at about $7 billion, people ...

Spring has nearly sprung and round two of the Inflation Reduction Act (IRA)’s negotiation period has begun. | All of the ...

All drug manufacturers, including Novo Nordisk and Teva Pharmaceuticals , whose medicines are part of the second round of ...

The stringent action is meant to prevent criticism of quality of drugs produced in the country and to prevent any non-tariff ...

Dublin-headquartered Mallinckrodt is taking over smaller rival Endo and planning to list the combined firm on the New York ...

Drugmakers have warned that a recent rise in the UK’s medicine sales tax has left the country “uninvestable”, as the government prepares for a summit to try to repair relationships with large ...

The pharmaceutical industry is urging the Trump administration and European Union to exclude medical goods from tariff ...

Endo shareholders will get $80 million in cash and own 49.9% of the combined company, while Mallinckrodt shareholders will ...

Endo shareholders will get $80 million in cash and own 49.9 per cent of the combined company, while Mallinckrodt shareholders ...

The agency will send an initial offer for each drug with its maximum fair price proposal no later than June 1, and the drugmakers will have 30 days to either accept it or provide a counteroffer.